• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Defective infectious particles and rare packaged genomes produced by cells carrying terminal-repeat-negative epstein-barr virus.携带末端重复序列阴性的爱泼斯坦-巴尔病毒的细胞产生的缺陷感染性颗粒和罕见包装基因组。
J Virol. 2005 Jun;79(12):7641-7. doi: 10.1128/JVI.79.12.7641-7647.2005.
2
BFRF1 of Epstein-Barr virus is essential for efficient primary viral envelopment and egress.爱泼斯坦-巴尔病毒的BFRF1对于有效的原发性病毒包膜化和释放至关重要。
J Virol. 2005 Mar;79(6):3703-12. doi: 10.1128/JVI.79.6.3703-3712.2005.
3
Structure and role of the terminal repeats of Epstein-Barr virus in processing and packaging of virion DNA.爱泼斯坦-巴尔病毒末端重复序列在病毒体DNA加工与包装中的结构和作用
J Virol. 1995 May;69(5):3147-55. doi: 10.1128/JVI.69.5.3147-3155.1995.
4
Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus.病毒重组体在针对爱泼斯坦-巴尔病毒免疫反应研究中的作用。
Semin Cancer Biol. 2008 Dec;18(6):409-15. doi: 10.1016/j.semcancer.2008.09.001. Epub 2008 Sep 30.
5
An Epstein-Barr virus mutant produces immunogenic defective particles devoid of viral DNA.一种 Epstein-Barr 病毒突变体能产生缺乏病毒 DNA 的免疫原性缺陷颗粒。
J Virol. 2013 Feb;87(4):2011-22. doi: 10.1128/JVI.02533-12. Epub 2012 Dec 12.
6
Terminal Repeat Analysis of EBV Genomes.
Methods Mol Biol. 2017;1532:169-177. doi: 10.1007/978-1-4939-6655-4_12.
7
Optimal lengths for DNAs encapsidated by Epstein-Barr virus.爱泼斯坦-巴尔病毒包裹的DNA的最佳长度
J Virol. 1994 Dec;68(12):8217-22. doi: 10.1128/JVI.68.12.8217-8222.1994.
8
Length of Epstein-Barr virus termini as a determinant of epithelial cell clonal emergence.爱泼斯坦-巴尔病毒末端长度作为上皮细胞克隆出现的决定因素。
J Virol. 2003 Aug;77(15):8555-61. doi: 10.1128/jvi.77.15.8555-8561.2003.
9
Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes.爱泼斯坦-巴尔病毒在人B淋巴细胞中永生化功能的遗传分析。
Nature. 1989 Aug 3;340(6232):393-7. doi: 10.1038/340393a0.
10
Epstein-Barr virus BALF3 has nuclease activity and mediates mature virion production during the lytic cycle.Epstein-Barr 病毒 BALF3 具有核酸酶活性,并在裂解周期中介导成熟病毒粒子的产生。
J Virol. 2014 May;88(9):4962-75. doi: 10.1128/JVI.00063-14. Epub 2014 Feb 19.

引用本文的文献

1
Evaluation of novel Epstein-Barr virus-derived antigen formulations for monitoring virus-specific T cells in pediatric patients with infectious mononucleosis.评价新型 Epstein-Barr 病毒衍生抗原制剂在监测传染性单核细胞增多症患儿病毒特异性 T 细胞中的作用。
Virol J. 2024 Jun 14;21(1):139. doi: 10.1186/s12985-024-02411-0.
2
EBV-associated diseases: Current therapeutics and emerging technologies.EBV 相关疾病:当前的治疗方法和新兴技术。
Front Immunol. 2022 Oct 27;13:1059133. doi: 10.3389/fimmu.2022.1059133. eCollection 2022.
3
Epstein-Barr Virus Infection in Lung Cancer: Insights and Perspectives.肺癌中的爱泼斯坦-巴尔病毒感染:见解与展望
Pathogens. 2022 Jan 21;11(2):132. doi: 10.3390/pathogens11020132.
4
Prophylactic and Therapeutic EBV Vaccines: Major Scientific Obstacles, Historical Progress, and Future Direction.预防性和治疗性EBV疫苗:主要科学障碍、历史进展及未来方向。
Vaccines (Basel). 2021 Nov 7;9(11):1290. doi: 10.3390/vaccines9111290.
5
Overview of virus and cancer relationships. Position paper.病毒与癌症关系概述。立场文件。
Rev Esp Quimioter. 2021 Dec;34(6):525-555. doi: 10.37201/req/058.2021. Epub 2021 Aug 5.
6
The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development.爱泼斯坦-巴尔病毒预防性疫苗研发的现状与前景
Front Immunol. 2021 Jun 8;12:677027. doi: 10.3389/fimmu.2021.677027. eCollection 2021.
7
Bone Marrow-Derived SH-SY5Y Neuroblastoma Cells Infected with Kaposi's Sarcoma-Associated Herpesvirus Display Unique Infection Phenotypes and Growth Properties.骨髓源性 SH-SY5Y 神经母细胞瘤细胞感染卡波西肉瘤相关疱疹病毒后显示独特的感染表型和生长特性。
J Virol. 2021 Jun 10;95(13):e0000321. doi: 10.1128/JVI.00003-21.
8
Vaccination against the Epstein-Barr virus.接种 EBV 疫苗。
Cell Mol Life Sci. 2020 Nov;77(21):4315-4324. doi: 10.1007/s00018-020-03538-3. Epub 2020 May 4.
9
Progress in EBV Vaccines.EB病毒疫苗的进展
Front Oncol. 2019 Feb 25;9:104. doi: 10.3389/fonc.2019.00104. eCollection 2019.
10
Epstein-Barr virus particles induce centrosome amplification and chromosomal instability.爱泼斯坦-巴尔病毒颗粒诱导中心体扩增和染色体不稳定性。
Nat Commun. 2017 Feb 10;8:14257. doi: 10.1038/ncomms14257.

本文引用的文献

1
Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future?人乳头瘤病毒疫苗作为预防宫颈癌的新方法:是梦想还是未来?
Ann Oncol. 2004 Feb;15(2):197-200. doi: 10.1093/annonc/mdh043.
2
CYTOLOGY OF BURKITT'S TUMOUR (AFRICAN LYMPHOMA).伯基特氏瘤(非洲淋巴瘤)的细胞学
Lancet. 1964 Feb 1;1(7327):238-40. doi: 10.1016/s0140-6736(64)92345-1.
3
Relationship of herpes simplex virus genome configuration to productive and persistent infections.单纯疱疹病毒基因组构型与增殖性感染和持续性感染的关系。
Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7871-6. doi: 10.1073/pnas.1230643100. Epub 2003 Jun 9.
4
Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection.爱泼斯坦-巴尔病毒的糖蛋白gp110决定病毒嗜性和感染效率。
Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15036-41. doi: 10.1073/pnas.232381299. Epub 2002 Oct 30.
5
The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structure.人类巨细胞病毒的末端酶亚基pUL56和pUL89是具有环形结构的DNA代谢蛋白。
Nucleic Acids Res. 2002 Apr 1;30(7):1695-703. doi: 10.1093/nar/30.7.1695.
6
A first-generation packaging cell line for Epstein-Barr virus-derived vectors.一种用于爱泼斯坦-巴尔病毒衍生载体的第一代包装细胞系。
Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5188-93. doi: 10.1073/pnas.96.9.5188.
7
Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells.完整、具有感染性的爱泼斯坦-巴尔病毒从原核细胞到人类细胞的传播与复苏。
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8245-50. doi: 10.1073/pnas.95.14.8245.
8
The gene product of human cytomegalovirus open reading frame UL56 binds the pac motif and has specific nuclease activity.人类巨细胞病毒开放阅读框UL56的基因产物结合pac基序并具有特定的核酸酶活性。
J Virol. 1998 Mar;72(3):2259-64. doi: 10.1128/JVI.72.3.2259-2264.1998.
9
Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.嵌合乳头瘤病毒样颗粒在HPV16肿瘤模型中引发针对E7癌蛋白的抗肿瘤免疫。
Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1800-5. doi: 10.1073/pnas.95.4.1800.
10
Sp1 binds to the precise locus of end processing within the terminal repeats of Epstein-Barr virus DNA.Sp1与爱泼斯坦-巴尔病毒DNA末端重复序列内的末端加工精确位点结合。
J Virol. 1997 Aug;71(8):6136-43. doi: 10.1128/JVI.71.8.6136-6143.1997.

携带末端重复序列阴性的爱泼斯坦-巴尔病毒的细胞产生的缺陷感染性颗粒和罕见包装基因组。

Defective infectious particles and rare packaged genomes produced by cells carrying terminal-repeat-negative epstein-barr virus.

作者信息

Feederle R, Shannon-Lowe C, Baldwin G, Delecluse H J

机构信息

German Cancer Research Center, Department of Virus-Associated Tumours, Im Neuenheimer Feld 242, 69120 Heidelberg, Germany.

出版信息

J Virol. 2005 Jun;79(12):7641-7. doi: 10.1128/JVI.79.12.7641-7647.2005.

DOI:10.1128/JVI.79.12.7641-7647.2005
PMID:15919916
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1143645/
Abstract

The Epstein-Barr virus (EBV) lytic program includes lytic viral DNA replication and the production of a viral particle into which the replicated viral DNA is packaged. The terminal repeats (TRs) located at the end of the linear viral DNA have been identified as the packaging signals. A TR-negative (TR(-)) mutant therefore provides an appropriate tool to analyze the relationships between EBV DNA packaging and virus production. Here, we show that supernatants from lytically induced 293 cells carrying TR mutant EBV genomes (293/TR(-)) contain large amounts of viral particles devoid of viral DNA which are nevertheless able to bind to EBV target cells. This shows that viral DNA packaging is not a prerequisite for virion formation and egress. Rather surprisingly, supernatants from lytically induced 293/TR(-) cells also contained rare infectious viruses carrying the viral mutant DNA. This observation indicates that the TRs are important but not absolutely essential for virus encapsidation.

摘要

爱泼斯坦-巴尔病毒(EBV)的裂解程序包括裂解性病毒DNA复制以及产生一个将复制的病毒DNA包装其中的病毒颗粒。位于线性病毒DNA末端的末端重复序列(TRs)已被确定为包装信号。因此,TR阴性(TR(-))突变体为分析EBV DNA包装与病毒产生之间的关系提供了一个合适的工具。在这里,我们发现,携带TR突变EBV基因组的裂解诱导293细胞(293/TR(-))的上清液中含有大量不含病毒DNA的病毒颗粒,但这些病毒颗粒仍能与EBV靶细胞结合。这表明病毒DNA包装不是病毒粒子形成和释放的先决条件。相当令人惊讶的是,裂解诱导的293/TR(-)细胞的上清液中还含有携带病毒突变DNA的罕见感染性病毒。这一观察结果表明,TRs对于病毒衣壳化很重要,但不是绝对必需的。